Tevogen Bio’s (TVGN) “Buy” Rating Reaffirmed at D. Boral Capital

Tevogen Bio (NASDAQ:TVGN)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock.

Tevogen Bio Trading Down 7.0 %

NASDAQ:TVGN opened at $1.06 on Tuesday. The stock has a 50-day simple moving average of $1.36 and a 200 day simple moving average of $1.16. Tevogen Bio has a 52-week low of $0.26 and a 52-week high of $7.61.

Insider Transactions at Tevogen Bio

In other news, insider Neal Flomenberg sold 88,519 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $1.10, for a total transaction of $97,370.90. Following the completion of the transaction, the insider now directly owns 4,040,485 shares in the company, valued at $4,444,533.50. This represents a 2.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 56.60% of the company’s stock.

Institutional Trading of Tevogen Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. bought a new position in Tevogen Bio in the fourth quarter valued at approximately $38,000. JPMorgan Chase & Co. boosted its holdings in shares of Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after buying an additional 16,695 shares during the last quarter. Barclays PLC grew its stake in shares of Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after buying an additional 12,847 shares in the last quarter. XTX Topco Ltd acquired a new position in Tevogen Bio during the fourth quarter worth $55,000. Finally, Northern Trust Corp raised its position in Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after acquiring an additional 13,595 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.